Madrigal sells the first approved drug for MASH fatty-liver disease.
Madrigal Pharmaceuticals, Inc. (MDGL) is expected to report earnings on Tuesday, November 3, 2026, before the open. Estimated release time 07:04 ET. Consensus EPS estimate is $-0.83.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-30 | Jun 2026 qtr | $-2.68 | $-1.99 | — | $364.25M |
| 2026-05-06 | Mar 2026 qtr | $-3.61 | $-3.25 | +10.0% | $311.34M |
| 2026-02-19 | Dec 2025 qtr | $0.04 | $-2.57 | — | $321.08M |
| 2025-08-05 | Jun 2025 qtr | $-3.48 | $-1.90 | — | $212.80M |
| 2025-05-01 | Mar 2025 qtr | $-3.62 | $-3.32 | +8.3% | $137.25M |
| 2025-02-26 | Dec 2024 qtr | — | $-2.71 | — | $103.32M |
| 2022-05-09 | Mar 2022 qtr | $-3.75 | $-3.36 | +10.4% | $0 |
MDGL has beaten consensus EPS in 3 of its last 3 scored quarters.
See MDGL on the live calendar →